Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT04704661
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
51 Enrollment(s)
23 Study location(s)
INTERVENTIONAL (PHASE1)
Advanced Breast Carcinoma


Advanced Colon Carcinoma


Advanced Colorectal Carcinoma


Advanced Endometrial Carcinoma


Advanced Gastric Carcinoma


Advanced Gastroesophageal Junction Adenocarcinoma


Advanced Malignant Solid Neoplasm


Advanced Salivary Gland Carcinoma


Anatomic Stage III Breast Cancer AJCC v8


Anatomic Stage IV Breast Cancer AJCC v8


Clinical Stage III Gastric Cancer AJCC v8


Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8


Clinical Stage IV Gastric Cancer AJCC v8


Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8


HER2-Positive Breast Carcinoma


Malignant Hepatobiliary Neoplasm


Metastatic Breast Carcinoma


Metastatic Colon Carcinoma


Metastatic Colorectal Carcinoma


Metastatic Endometrial Carcinoma


Metastatic Gastric Carcinoma


Metastatic Gastroesophageal Junction Adenocarcinoma


Metastatic Malignant Solid Neoplasm


Metastatic Salivary Gland Carcinoma


Stage III Colon Cancer AJCC v8


Stage III Colorectal Cancer AJCC v8


Stage III Major Salivary Gland Cancer AJCC v8


Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Stage IV Colon Cancer AJCC v8


Stage IV Colorectal Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Unresectable Breast Carcinoma


Unresectable Colon Carcinoma


Unresectable Colorectal Carcinoma


Unresectable Endometrial Carcinoma


Unresectable Gastric Carcinoma


Unresectable Gastroesophageal Junction Adenocarcinoma


Unresectable Malignant Solid Neoplasm


Unresectable Salivary Gland Carcinoma
RECRUITING
NCT07012031
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
37 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Locally Advanced Lung Non-Small Cell Carcinoma


Metastatic Lung Non-Small Cell Carcinoma


Stage III Lung Cancer AJCC v8


Stage IV Lung Cancer AJCC v8
NOT_YET_RECRUITING
NCT06650501
Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia
300 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Staphylococcus Aureus Endocarditis


Staphylococcus Aureus Septicemia


Staphylococcus Aureus Bacteremia


Staphylococcus Aureus Bloodstream Infection


S. Aureus Bacteremia


S. Aureus Bloodstream Infection
RECRUITING
NCT06429761
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
100 Enrollment(s)
6 Study location(s)
INTERVENTIONAL (PHASE4)
BREAST CANCER
RECRUITING
NCT05573893
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
800 Enrollment(s)
104 Study location(s)
OBSERVATIONAL (None)
Breast Neoplasms


Breast Cancer


Neoplasm Metastasis
RECRUITING
NCT05417594
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
695 Enrollment(s)
33 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Solid Malignancies
COMPLETED
NCT04644237
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
152 Enrollment(s)
50 Study location(s)
INTERVENTIONAL (PHASE2)
Non-Small Cell Lung Cancer
RECRUITING
NCT04482309
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
468 Enrollment(s)
123 Study location(s)
INTERVENTIONAL (PHASE2)
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer


Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer